Search

Your search keyword '"Pecorelli, Sergio"' showing total 760 results
Start Over Author "Pecorelli, Sergio"
760 results on '"Pecorelli, Sergio"'

1. Towards a Framework for a New Research Ecosystem

Author

Savona, Roberto, Alberini, Cristina Maria, Alessi, Lucia, Baussano, Iacopo, Dellaportas, Petros, Guerra, Ranieri, Khozin, Sean, Modena, Andrea, Pecorelli, Sergio, Rasi, Guido, Siviero, Paolo Daniele, and Stein, Roger M.

Subjects
Economics - General Economics
Abstract

A major gap exists between the conceptual suggestion of how much a nation should invest in science, innovation, and technology, and the practical implementation of what is done. We identify 4 critical challenges that must be address in order to develop an environment conducive to collaboration across organizations and governments, while also preserving commercial rewards for investors and innovators, in order to move towards a new Research Ecosystem., Comment: 20 pages, 1 table, 2 figures

Published
2023

2. Integrated mutational landscape analysis of uterine leiomyosarcomas

Author

Choi, Jungmin, Manzano, Aranzazu, Dong, Weilai, Bellone, Stefania, Bonazzoli, Elena, Zammataro, Luca, Yao, Xiaotong, Deshpande, Aditya, Zaidi, Samir, Guglielmi, Adele, Gnutti, Barbara, Nagarkatti, Nupur, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Jeong, Kyungjo, Zhao, Siming, Buza, Natalia, Hui, Pei, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Bilguvar, Kaya, Quick, Charles M., Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Ratner, Elena, Azodi, Masoud, Imielinski, Marcin, Schwartz, Peter E., Alexandrov, Ludmil B., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2021

3. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Author

Zammataro, Luca, Lopez, Salvatore, Bellone, Stefania, Pettinella, Francesca, Bonazzoli, Elena, Perrone, Emanuele, Zhao, Siming, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Zeybek, Burak, Bianchi, Anna, Manzano, Aranzazu, Manara, Paola, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Donzelli, Carla, Ardighieri, Laura, Angioli, Roberto, Raspagliesi, Francesco, Scambia, Giovanni, Choi, Jungmin, Dong, Weilai, Bilguvar, Kaya, Alexandrov, Ludmil B., Silasi, Dan-Arin, Huang, Gloria S., Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Pirazzoli, Valentina, Stiegler, Amy L., Boggon, Titus J., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2019

6. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitor

Author

Li, Charles, Bonazzoli, Elena, Bellone, Stefania, Choi, Jungmin, Dong, Weilai, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Manzano, Aranzazu, Bianchi, Anna, Pettinella, Francesca, Manara, Paola, Lopez, Salvatore, Yadav, Ghanshyam, Riccio, Francesco, Zammataro, Luca, Zeybek, Burak, Yang-Hartwich, Yang, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Zizioli, Valentina, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Silasi, Dan-Arin, Litkouhi, Babak, Ratner, Elena, Azodi, Masoud, Huang, Gloria S., Schwartz, Peter E., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2019

8. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

Author

Zhao, Siming, Bellone, Stefania, Lopez, Salvatore, Thakral, Durga, Schwab, Carlton, English, Diana P., Black, Jonathan, Cocco, Emiliano, Choi, Jungmin, Zammataro, Luca, Predolini, Federica, Bonazzoli, Elena, Bi, Mark, Buza, Natalia, Hui, Pei, Wong, Serena, Abu-Khalaf, Maysa, Ravaggi, Antonella, Bignotti, Eliana, Bandiera, Elisabetta, Romani, Chiara, Todeschini, Paola, Tassi, Renata, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Donzelli, Carla, Ardighieri, Laura, Facchetti, Fabio, Falchetti, Marcella, Silasi, Dan-Arin, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Mane, Shrikant, Angioli, Roberto, Terranova, Corrado, Quick, Charles Matthew, Edraki, Babak, Bilgüvar, Kaya, Lee, Moses, Choi, Murim, Stiegler, Amy L., Boggon, Titus J., Schlessinger, Joseph, Lifton, Richard P., and Santin, Alessandro D.

Published
2016

9. The introduction of policies for human papillomavirus vaccination in Europe

Author

Van Damme, Pierre, Pecorelli, Sergio, and Joura, Elmar

Abstract

Abstract: Background: Human papillomavirus (HPV) vaccines represent a major advance in the prevention of cervical cancer and other HPV-related diseases. The availability of HPV vaccination and cervical cancer screening creates the unique opportunity to combine primary and secondary prevention of a cancer. HPV vaccination is currently being adopted in Europe at a faster rate than has been seen with most previous vaccines. Aims and methods: This article analyses the reasons for the rapid and broad access to this cancer prevention measure to illustrate the new sociopolitical environment that drives vaccination policies in the 21st century. Results: The promise of this intervention to prevent infection by the virus that can cause these diseases in young women created an environment receptive to vaccination. However, it was robust data generated by research specifically targeted to public health needs that have convinced various stakeholders to advocate, license, recommend, and fund vaccination. It was not just the usual host of actors who rallied to this process: early support for decision-making came from experts and scientific societies, patient and women’s groups, and policy makers at the EU and national levels. Implementation now looms as the greatest challenge to vaccine uptake, in particular in the adolescent target group. Determinants of successful implementation include well-informed healthcare professionals who in turn can educate parents and adolescents on the infectious disease, its consequences, and the efficacy and safety of vaccination, and successful provision of equitable access to vaccination. The integration of vaccination and screening must also be carefully managed and adapted to the situation in each country. Conclusion: Inevitably, the impact of this promising public health intervention will depend upon the continuing engagement of all stakeholders to maintain interest and confidence in vaccination.

Published
2024
Full Text
View/download PDF

10. Perspective: Improving Nutritional Guidelines for Sustainable Health Policies: Current Status and Perspectives

Author

Magni, Paolo, Bier, Dennis M, Pecorelli, Sergio, Agostoni, Carlo, Astrup, Arne, Brighenti, Furio, Cook, Robert, Folco, Emanuela, Fontana, Luigi, Gibson, Robert A, Guerra, Ranieri, Guyatt, Gordon H, Ioannidis, John PA, Jackson, Ann S, Klurfeld, David M, Makrides, Maria, Mathioudakis, Basil, Monaco, Alessandro, Patel, Chirag J, Racagni, Giorgio, Schünemann, Holger J, Shamir, Raanan, Zmora, Niv, and Peracino, Andrea

Published
2017
Full Text
View/download PDF

11. Supplemental Material Section S5 from miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

Author

Calura, Enrica, primary, Fruscio, Robert, primary, Paracchini, Lara, primary, Bignotti, Eliana, primary, Ravaggi, Antonella, primary, Martini, Paolo, primary, Sales, Gabriele, primary, Beltrame, Luca, primary, Clivio, Luca, primary, Ceppi, Lorenzo, primary, Di Marino, Mariacristina, primary, Fuso Nerini, Ilaria, primary, Zanotti, Laura, primary, Cavalieri, Duccio, primary, Cattoretti, Giorgio, primary, Perego, Patrizia, primary, Milani, Rodolfo, primary, Katsaros, Dionyssios, primary, Tognon, Germana, primary, Sartori, Enrico, primary, Pecorelli, Sergio, primary, Mangioni, Costantino, primary, D'Incalci, Maurizio, primary, Romualdi, Chiara, primary, and Marchini, Sergio, primary

Published
2023
Full Text
View/download PDF

13. COVID-19 vaccine literacy: A scoping review

Author

Biasio, Luigi Roberto, primary, Zanobini, Patrizio, additional, Lorini, Chiara, additional, Monaci, Pietro, additional, Fanfani, Alice, additional, Gallinoro, Veronica, additional, Cerini, Gabriele, additional, Albora, Giuseppe, additional, Del Riccio, Marco, additional, Pecorelli, Sergio, additional, and Bonaccorsi, Guglielmo, additional

Published
2023
Full Text
View/download PDF

14. Public health value of universal HPV vaccination

Author

Audisio, Riccardo A., Icardi, Giancarlo, Isidori, Andrea M., Liverani, Carlo A., Lombardi, Alberto, Mariani, Luciano, Mennini, Francesco Saverio, Mitchell, David A., Peracino, Andrea, Pecorelli, Sergio, Rezza, Giovanni, Signorelli, Carlo, Rosati, Giovanni Vitali, and Zuccotti, Gian Vincenzo

Published
2016
Full Text
View/download PDF

16. Differential Effects of High-Dose Gamma Irradiation on the Production of Transforming Growth Factor-Beta in Fresh and Established Human Ovarian Cancer

Author

Santin, Alessandro D, Hiserodt, John C, DiSaia, Philip J, Pecorelli, Sergio, and Granger, Gale A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Ovarian Cancer, Aetiology, 2.1 Biological and endogenous factors, Antineoplastic Agents, Female, Gamma Rays, Humans, Interferon-gamma, Ovarian Neoplasms, Radiotherapy Dosage, Transforming Growth Factor beta, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

Tumor cells from five freshly isolated ovarian tumors and four established human ovarian carcinoma cell lines were analyzed for the production of the immunoinhibitory cytokine transforming growth factor-beta (TGF-beta) before and after exposure to gamma irradiation and/or the cytokines TNF-alpha plus IFN-gamma. All fresh tumors secreted high levels of TGF-beta when compared to the levels produced by the established ovarian carcinoma cell lines. TGF-beta produced by fresh tumors was significantly reduced after high doses of gamma irradiation (10,000 cGy). In contrast with the established cell lines, irradiation significantly increased TGF-beta secretion. Exposure of fresh tumor cells to cytokines followed by irradiation caused significant reduction of TGF-beta released when compared to the amount released after exposure to cytokines only. However, in the established cell lines, cytokines followed by irradiation again significantly increased TGF-beta production. These data indicate that high doses of irradiation in fresh ovarian tumors, unlike established ovarian carcinoma cell lines, can significantly reduce the local production of this potent immunoinhibitory cytokine. This effect could work to further amplify weak immunological responses within the tumor. In addition, these findings indicate major differences between fresh tumor samples and established cell lines and warn against the sole use of continuous cell lines as models for tumors growing in vivo.

Published
1996

17. Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer

Author

Santin, Alessandro D, Hiserodt, John C, Fruehauf, John, DiSaia, Philip J, Pecorelli, Sergio, and Granger, Gale A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Rare Diseases, Cancer, Ovarian Cancer, Aetiology, 2.1 Biological and endogenous factors, Antigens, Neoplasm, Antigens, Surface, Carcinoma, Dose-Response Relationship, Radiation, Female, Gamma Rays, Humans, Kinetics, Ovarian Neoplasms, Tumor Cells, Cultured, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

Tumor cells from four established human ovarian carcinoma cell lines were analyzed for their expression of surface antigens including MHC Class I, Class II, ICAM-1, and the tumor-associated antigens CA 125 and Her2-neu before and after exposure to high doses of gamma irradiation. All four ovarian cell IInes expressed variable levels of MHC Class I and Her2-neu. ICAM-1 antigens were expressed in only two cell lines and Class II and CA 125 surface antigens were absent in all the cell lines evaluated. Exposure to high doses of gamma irradiation (i.e., 5000 to 10,000 cGy) significantly and consistently increased the expression of all surface antigens present on the cells prior to irradiation. Importantly, the irradiation-induced upregulation was persistent and lasted until all the cells died. Irradiation was unable to induce neoexpression of antigens previously not expressed by the cells (i.e., MHC Class II or ICAM-1). These findings may partially explain the increased immunogenicity of tumor cells following irradiation and may suggest enhanced immune recognition in tumor tissue in patients receiving radiation therapy.

Published
1996

18. Effects of cytokines combined with high‐dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule‐1 in human ovarian cancers

Author

Santin, Alessandro D, Rose, G Scott, Hiserodt, John C, Fruehauf, John, Eck, Lawrence M, Garcia, Roxana I, Schranz, Viktor, Disaia, Philip J, Pecorelli, Sergio, and Granger, Gale A

Subjects
Cancer, Ovarian Cancer, Human Genome, Vaccine Related, Rare Diseases, Genetics, Immunization, Inflammatory and immune system, Adenocarcinoma, Female, Gamma Rays, Histocompatibility Antigens Class I, Humans, Intercellular Adhesion Molecule-1, Interferon-gamma, Ovarian Neoplasms, Tumor Necrosis Factor-alpha, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Tumor cells from 7 freshly isolated human ovarian tumors and 2 continuous human ovarian cancer cell lines were analyzed for their surface expression of MHC class-1, class 11 and ICAM-1 surface antigens before and after exposure to gamma-irradiation and/or the cytokines TNF-alpha plus IFN-gamma. All 7 fresh tumors expressed high levels of MHC class 1 and 1CAM-1 antigens, and levels were markedly up-regulated after exposure to TNF-alpha plus IFN-gamma Similarly, class-11 antigens were either induced (3 out of 7 tumors) or significantly up-regulated by TNF-alpha plus IFN-gamma. Exposure to high doses of gamma-irradiation also increased the expression of MHC class-1 and ICAM-1 antigens, albeit to a modest degree. MHC class 1 and ICAM-1 antigens expression was much lower on continuous human ovarian cell lines than on the fresh tumors. Exposure of these cells to TNF-alpha plus IFN-gamma markedly up-regulated antigen expression to levels comparable to those expressed on the freshly isolated tumors. With the established ovarian cell lines, removal of cytokines caused a rapid down-regulation of antigen expression to basal levels within 6 days, while in the fresh tumors a low level of up-regulation was still present at this time. In contrast, exposure to cytokines followed by high-dose gamma-irradiation resulted in a highly significant and long-lasting expression of each surface antigen which was either up-regulated or induced by the cytokines. These data indicated that the combination of these modalities may be beneficial in generating optimal antigen expression for use of tumor cells in vaccine studies.

Published
1996

19. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules

Author

Santin, Alessandro D, Ioli, Gene R, Hiserodt, John C, Manetta, Alberto, Pecorelli, Sergio, DiSaia, Philip J, and Granger, Gale A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Ovarian Cancer, Stem Cell Research - Nonembryonic - Non-Human, Biotechnology, Stem Cell Research, Rare Diseases, Vaccine Related, Immunization, 2.1 Biological and endogenous factors, Aetiology, Adenocarcinoma, Papillary, Animals, Cytotoxicity, Immunologic, Female, Histocompatibility Antigens Class I, Humans, Interleukin-2, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Transplantation, Ovarian Neoplasms, Receptor, ErbB-2, Transfection, Tumor Cells, Cultured, Vaccines, interleukin-2, ovarian cancer, tumor vaccine, Receptor, erbB-2, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine, Reproductive medicine
Abstract

ObjectiveWe initiated studies to develop cytokine-secreting human ovarian carcinoma cells for the purpose of using these cells as vaccines for the treatment of advanced epithelial ovarian cancer.Study designA human ovarian carcinoma cell line (UCI-107) was genetically engineered to secrete the cytokine interleukin-2 by retroviral-mediated gene transduction.ResultsOne clone, termed UCI-107A IL-2 AS, constitutively secreted high levels of interleukin-2 (i.e., 2000 to 2300 pg/ml/10(5) cells per 48 hours) for > 55 passages and 8 months of study. Unlike parental- and vector-transduced cells, UCI-107A IL-2 AS cells were aneuploid and failed to express major histocompatibility complex class I and HER2/neu surface antigens. UCI-107A IL-2 AS cells were highly resistant to killing by gamma irradiation and continued to produce high levels of interleukin-2 even after irradiation with 10,000 cGy. Balb/C nude mice injected intraperitoneally with UCI 107-A IL-2 AS cells survived significantly longer than control animals, with 25% of the animals totally rejecting their tumors. UCI-107A IL-2 AS was totally resistant to killing by fresh allogeneic peripheral blood lymphocytes in four hour chromium 51 release assays but induced high levels of killing in 72-hour long-term cytotoxic assays.ConclusionThe potential use of these interleukin-2-secreting ovarian carcinoma cells as vaccines for women with advance ovarian cancer will be discussed.

Published
1996

20. Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line

Author

Santin, Alessandro D, Ioli, Gene R, Hiserodt, John C, Rose, G Scott, Graf, Martin R, Tocco, Lisa M, Lander, Jeffrey K, Eck, Lawrence M, Burger, Robert A, DiSaia, Philip J, Pecorelli, Sergio, and Granger, Gale A

Subjects
Biomedical and Clinical Sciences, Immunology, Rare Diseases, Cancer, Ovarian Cancer, Antigens, Neoplasm, Antigens, Surface, Cell Division, Cell Survival, Clone Cells, Cystadenocarcinoma, Papillary, DNA, Neoplasm, DNA, Viral, Female, Genetic Vectors, Histocompatibility Antigens Class I, Humans, Intercellular Adhesion Molecule-1, Interleukin-4, Kinetics, Ovarian Neoplasms, Plasmids, Retroviridae, Transduction, Genetic, Tumor Cells, Cultured, Vaccines, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

Human ovarian carcinoma cell lines were genetically engineered to secrete the cytokine interleukin-4 (IL-4) by retroviral-mediated gene transduction. These cells were transduced with the LXSN retroviral vector containing the human IL-4 gene and the neomycin resistance selection marker. Numerous IL-4-secreting clones were isolated from different papillary serous carcinoma cell lines, including SKOV-3, UCI-101, and UCI-107, and one clone derived from UCI-107 extensively characterized. This clone, termed UCI 107E IL-4 GS, was shown to constitutively express high levels of IL-4 (i.e., 900 to 1300 pg/ml/10(5) cells/48 hr) for over 35 passages and 6 months of study. Like the parental cell line (UCI-107), UCI 107E IL-4 GS cells expressed MHC class I and Her-2/neu surface antigens but did not express detectable MHC class II, ICAM 1, CA 125, or IL-4 receptors. No increase in expression of surface proteins was noted between parental and UCI 107E IL-4 GS. The morphology of this clone did not differ from that of the parental or LXSN vector control cells; however, parental cells had a faster growth rates than transductants. UCI 107E IL-4 GS was sensitive to gamma irradiation since as little as 2500 rad killed most of the cells within 10 days of irradiation. However, after irradiation, IL-4 secretion continued until about Day 8. The potential use of these IL-4-secreting ovarian carcinoma cells as vaccines for woman with advanced ovarian cancer will be discussed.

Published
1995

26. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference

Author

Baiocchi, Gian Luca, D’Ugo, Domenico, Coit, Daniel, Hardwick, Richard, Kassab, Paulo, Nashimoto, Atsushi, Marrelli, Daniele, Allum, William, Berruti, Alfredo, Chandramohan, Servarayan Murugesan, Coburn, Natalie, Gonzàlez-Moreno, Santiago, Hoelscher, Arnulf, Jansen, Edwin, Leja, Marcis, Mariette, Christophe, Meyer, Hans-Joachim, Mönig, Stefan, Morgagni, Paolo, Ott, Katia, Preston, Shaun, Rha, Sun Young, Roviello, Franco, Sano, Takeshi, Sasako, Mitsuru, Shimada, Hideaki, Schuhmacher, Cristoph, So Bok-yan, Jimmy, Strong, Vivian, Yoshikawa, Takaki, Terashima, Masanori, Ter-Ovanesov, Michail, Van der Velde, Cornelis, Memo, Maurizio, Castelli, Francesco, Pecorelli, Sergio, Detogni, Claudio, Kodera, Yasuhiro, and de Manzoni, Giovanni

Published
2016
Full Text
View/download PDF

27. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

Author

Zhao, Siming, Choi, Murim, Overton, John D., Bellone, Stefania, Roque, Dana M., Cocco, Emiliano, Guzzo, Federica, English, Diana P., Varughese, Joyce, Gasparrini, Sara, Bortolomai, Ileana, Buza, Natalia, Hui, Pei, Abu-Khalaf, Maysa, Ravaggi, Antonella, Bignotti, Eliana, Bandiera, Elisabetta, Romani, Chiara, Todeschini, Paola, Tassi, Renata, Zanotti, Laura, Carrara, Luisa, Pecorelli, Sergio, Silasi, Dan-Arin, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Rutherford, Thomas J., Stiegler, Amy L., Mane, Shrikant, Boggon, Titus J., Schlessinger, Joseph, Lifton, Richard P., and Santin, Alessandro D.

Published
2013

35. Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer

Author

Cocco, Emiliano, Shapiro, Erik M., Gasparrini, Sara, Lopez, Salvatore, Schwab, Carlton L., Bellone, Stefania, Bortolomai, Ileana, Sumi, Natalia J., Bonazzoli, Elena, Nicoletti, Roberta, Deng, Yang, Saltzman, Mark W., Zeiss, Caroline J., Centritto, Floriana, Black, Jonathan D., Silasi, Dan-Arin, Ratner, Elena, Azodi, Masoud, Rutherford, Thomas J., Schwartz, Peter E., Pecorelli, Sergio, and Santin, Alessandro D.

Published
2015
Full Text
View/download PDF

38. The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic

Author

Monaco, Alessandro, primary, Casteig Blanco, Amaia, additional, Cobain, Mark, additional, Costa, Elisio, additional, Guldemond, Nick, additional, Hancock, Christine, additional, Onder, Graziano, additional, Pecorelli, Sergio, additional, Silva, Mitchell, additional, Tournoy, Jos, additional, Trevisan, Caterina, additional, Votta, Mariano, additional, Yfantopoulos, John, additional, Yghemonos, Stecy, additional, Clay, Vincent, additional, Mondello Malvestiti, Franco, additional, De Schaetzen, Karine, additional, Sykara, Georgia, additional, and Donde, Shaantanu, additional

Published
2021
Full Text
View/download PDF

39. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database

Author

Fadini, Gian Paolo, Avogaro, Angelo, Degli Esposti, Luca, Russo, Pierluigi, Saragoni, Stefania, Buda, Stefano, Rosano, Giuseppe, Pecorelli, Sergio, Pani, Luca, Martinetti, S., Mero, P., Raeli, L., Migliazza, S., Dellagiovanna, M., Cerra, C., Gambera, M., Piccinelli, R., Zambetti, M., Atzeni, F., Valsecchi, V., DeLuca, P., Scopinaro, E., Moltoni, D., Pini, E., Leoni, O., Oria, C., Papagni, M., Nosetti, G., Caldiroli, E., Moser, V., Roni, R., Polverino, A., Bovo, C., Mezzalira, L., Andretta, M., Trentin, L., Palcic, S., Pettinelli, A., Arbo, A., Bertola, A., Capparoni, G., Cattaruzzi, C., Marcuzzo, L., Rosa, F.V., Basso, B., Saglietto, M., Delucis, S., Prioli, M., Filippi, R., Coccini, A., Ghia, M., Sanfelici, F., Radici, S., Scanavacca, P., Campi, A., Bianchi, S., Verzola, A., Morini, M., Borsari, M., Danielli, A., Dal Maso, M., Marsiglia, B., Vujovic, B., Pisani, M., Bonini, P., Lena, F., Aletti, P., Marcobelli, A., Sagratella, S., Fratini, S., Bartolini, F., Riccioni, G., Meneghini, A., Di Turi, R., Fano, V., Blasi, A., Pagnozzi, E., Quintavalle, G., DʼAvenia, P., De Matthaeis, M.C., Ferrante, F., Crescenzi, S., Marziale, L., Venditti, P., Bianchi, C., Senesi, I., Baci, R., De Carlo, I., Lavalle, A., Trofa, G., Marcello, G., Pagliaro, C., Troncone, C., Farina, G., Tari, M.G., Motola, G., De Luca, F., Saltarelli, M.L., Granieri, C., Vulnera, M., Palumbo, L., La Viola, F., Florio, L., De Francesco, A.E., Costantino, D., De Francesco, A.E., Rapisarda, F., Lazzaro, P.L., Pastorello, M., Parlli, M., Visconti, M., Uomo, I., Sanna, P., and Lombardo, F.

Published
2015
Full Text
View/download PDF

41. The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic

Author

Monaco, Alessandro Casteig Blanco, Amaia Cobain, Mark Costa, Elisio Guldemond, Nick Hancock, Christine Onder, Graziano and Pecorelli, Sergio Silva, Mitchell Tournoy, Jos Trevisan, Caterina Votta, Mariano Yfantopoulos, John Yghemonos, Stecy and Clay, Vincent Mondello Malvestiti, Franco De Schaetzen, Karine Sykara, Georgia Donde, Shaantanu

Abstract

Background Policies to combat the COVID-19 pandemic have disrupted the screening, diagnosis, treatment, and monitoring of noncommunicable (NCD) patients while affecting NCD prevention and risk factor control. Aims To discuss how the first wave of the COVID-19 pandemic affected the health management of NCD patients, identify which aspects should be carried forward into future NCD management, and propose collaborative efforts among public-private institutions to effectively shape NCD care models. Methods The NCD Partnership, a collaboration between Upjohn and the European Innovation Partnership on Active and Healthy Ageing, held a virtual Advisory Board in July 2020 with multiple stakeholders; healthcare professionals (HCPs), policymakers, researchers, patient and informal carer advocacy groups, patient empowerment organizations, and industry experts. Results The Advisory Board identified barriers to NCD care during the COVID-19 pandemic in four areas: lack of NCD management guidelines; disruption to integrated care and shift from hospital-based NCD care to more community and primary level care; infodemics and a lack of reliable health information for patients and HCPs on how to manage NCDs; lack of availability, training, standardization, and regulation of digital health tools. Conclusions Multistakeholder partnerships can promote swift changes to NCD prevention and patient care. Intra- and inter-communication between all stakeholders should be facilitated involving all players in the development of clinical guidelines and digital health tools, health and social care restructuring, and patient support in the short-, medium- and long-term future. A comprehensive response to NCDs should be delivered to improve patient outcomes by providing strategic, scientific, and economic support.

Published
2021

44. Medical-health recommendations for the Serie A League

Author

CASASCO, Maurizio, primary, PECORELLI, Sergio, additional, CORSINI, Alessandro, additional, DE FERRARI, Francesco, additional, GALLI, Massimo, additional, MEMO, Maurizio, additional, MORI, Luigi, additional, NOVELLI, Giuseppe, additional, SIGNORELLI, Carlo, additional, VERZELETTI, Andrea, additional, and PIGOZZI, Fabio, additional

Published
2021
Full Text
View/download PDF

48. Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology

Author

Fredolini, Claudia, Meani, Francesco, Luchini, Alessandra, Zhou, Weidong, Russo, Paul, Ross, Mark, Patanarut, Alexis, Tamburro, Davide, Gambara, Guido, Ornstein, David, Odicino, Franco, Ragnoli, Monica, Ravaggi, Antonella, Novelli, Francesco, Collura, Devis, D’Urso, Leonardo, Muto, Giovanni, Belluco, Claudio, Pecorelli, Sergio, Liotta, Lance, and Petricoin, III, Emanuel F.

Published
2010
Full Text
View/download PDF

50. Neoadjuvant chemotherapy of primary surgery in stage IIIC or IV ovarian cancer

Author

Vergote, Ignace, Trope, Glaes G., Amant, Frederic, Kristensen, Gunnar B., Ehlen, Tom, Johnson, Nick, Verheijen, Rene H.M., van der Burg, Maria E.L., Lacave, Angel J., Panici, Pierluigi Benedetti, Kenter, Gemma C., Casado, Antonio, Mendiola, Cesar, Coens, Corneel, Verleye, Leen, Stuart, Gavin C.E., Pecorelli, Sergio, and Reed, Nick S.

Subjects
Neoadjuvant therapy -- Comparative analysis, Neoadjuvant therapy -- Patient outcomes, Ovarian cancer -- Care and treatment, Surgery -- Comparative analysis, Surgery -- Patient outcomes
Abstract

The study attempts to evaluate and compare the efficacy of neoadjuvant chemotherapy followed by interval debunking surgery as a treatment option in stage IIIC or IV ovarian cancer as against debunking surgery followed by chemotherapy. The results indicate that both forms of treatment had similar outcomes.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results